Neuroprotective effects of caffeine in the model of 6-hydroxydopamine lesion in rats

Pharmacology Biochemistry and Behavior

Volumn 84, Issue 3, 2006, Pages 415-419

  Aguiar, Lissiana Magna Vasconcelos ^a   Nobre Jr , Hélio V ^a   Macêdo, Danielle S ^a   Oliveira, Aline A ^a   Freitas, Rivelilson M ^a   Vasconcelos, Silvânia M ^a   Cunha, Geanne M A ^a   Sousa, Francisca Cléa F ^a   Viana, Glauce Socorro B ^a  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

Author keywords

6 Hydroxydopamine; Caffeine; Parkinson's disease; Rat striatum

Indexed keywords

APOMORPHINE; CAFFEINE; DOPAMINE; MONOAMINE; NORADRENALIN; OXIDOPAMINE;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; BRAIN LEVEL; BRAIN NERVE CELL; CELL LOSS; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; MALE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMALS; APOMORPHINE; BRAIN; BRAIN DISEASES; CAFFEINE; DISEASE MODELS, ANIMAL; DOPAMINE AGENTS; MALE; NEURONS; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, WISTAR;

ANIMALIA;

EID: 33747888208     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2006.05.027     Document Type: Article

References (25)

1. Ahmadi F.A., Linseman D.A., Grammatopoulos T.N., Jones S.M., Bouchard R.J., Freed C.R., et al. The pesticide retonone induces caspase-3-mediated apoptosis in ventral mesencephalic dopaminergic neurons. J Neurochem 87 (2003) 914-921
2. Alfavaro T.M., Vigra E., Oliveira C.R., and Cunha R.A. Effect of free radicals on adenosine A (2A) and dopamine D2 receptors in the striatum of young adult and aged rats. Neurochem Int 45 (2004) 733-738
3. Baraldi P.G., Tabrizi M.A., Bovero A., Avitabile B., Petri D., Fruttarolo F., et al. Recent developments in the field of A2A and A3 adenosine receptor antagonists. Eur J Med Chem (2003) 1-16
4. Cauli O., Pinna A., and Morelli M. Subchronic intermittent caffeine administration to unilaterally 6-hydroxydopamine-lesioned rats sensitizes turning behaviour in response to dopamine D(1) but not D(2) receptor agonists. Behav Pharmacol 16 (2005) 621-626
5. Chen J.F., Steyn S., Staal R., Petzer J.P., Xu K., Van Der Schyf C.J., et al. 8-(3-Chlorostyryl) caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism. J Biol Chem 277 (2002) 36040-36044
6. Fisone G., Borgkvist A., and Usiello A. Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci 61 (2004) 857-872
7. Fredholm B.B., and Svenningsson P. Adenosine-dopamine interactions: development of a concept and some comments on therapeutic possibilities. Neurology 61 11 Suppl 6 (2003) S-5-9
8. Fredholm B.B., Battig K., Holmen J., Nehlig A., and Zvartau E.E. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharm Rev 51 (1999) 83-133
9. Hudson J.L., Van Horne C.G., Strömberg I., Brock S., Clayton J., Masserano J., et al. Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res 626 (1993) 167-174
10. Ichitani Y., Okamura H., Nakahara D., Nagatsu I., and Ibata Y. Biochemical and immunocytochemical changes induced by intrastriatal 6-hydroxydopamine injection in the rat nigrostriatal dopamine neuron system: evidence for cell death in the substantia nigra. Exp Neurol 130 (1994) 269-278
11. 2A receptor blockade in experimental models of Parkinson's disease. J Neurochem 80 (2002) 262-270
12. Ishiwata K., Mishina M., Kimura Y., Oda K., Sasaki T., and Ishii K. First visualization of adenosine A(2A) receptors in the human brain by positron emission tomography with [11C]TMSX. Synapse 55 (2005) 133-136
13. Joghataie M.T., Roghani M., Negahdar F., and Hashemi L. Protective effect of caffeine against neurodegeneration in a model of Parkinson's disease in rat: behavioral and histochemical evidence. Parkinsonism Relat Disord 10 (2004) 465-468
14. Lee C. Antioxidant ability of caffeine and its metabolites based on the study of oxygen radical absorpting capacity and inhibition of LDL peroxidation. Clin Chim Acta 295 (2000) 141-154
15. Moo-Puc R.E., Góngora-Alfaro J.L., Alvarez-Cervera F.J., Pineda J.C., Arankowsky-Sandoval G., and Heredia-López F. Caffeine and muscarinic antagonists act in synergy to inhibit haloperidol-induced catalepsy. Neuropharmacology 45 (2003) 493-503
16. Morelli M. Adenosine A2A antagonists: potential preventive and palliative treatment for Parkinson's disease. Exp Neurol 184 (2003) 20-23
17. Oztas E., Kalda A., Xu K., Irrizary M.C., Schwarzschild M.A., and Chen J.F. Caffeine attenuates MPTP-induced loss of dopaminergic neurons in substantia nigra in mice. Program No. 487.6 (2002), Society for Neuroscience, Washington, DC Online
18. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates. 2nd Ed. (1986), Academic Press, New York
19. Pierri M., Valdano E., Sager T., and Englund U. KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse. Neuropharmacology 48 (2005) 517-524
20. Ravina B.M., Fagan S.C., Hart R.G., Hovinga C.A., Murphy D.D., Dawson T.M., et al. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 60 (2003) 1234-1240
21. Ross G.W., and Petrovitch H. Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease. Drugs Aging 18 (2001) 797-806
22. Ross G.W., Abbott R.D., Petrovitch H., Morens D.M., Grandinetti A., and Tung K.H. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 283 (2000) 2674-2679
23. Schwarzschild M.A., Chen J.F., and Ascherio A. Caffeinated clues and the promise of adenosine A(2A) antagonists in PD. Neurology 58 (2002) 1154-1160
24. 2A receptor antagonists in Parkinson's disease. Pharmacol Ther 105 (2005) 267-310
25. Yu L., Schwarzschild M.A., and Chen J.F. Cross-sensitization between caffeine- and l-dopa-induced behaviors in hemiparkinsonian mice. Neurosci Lett 393 (2006) 31-35